Eyeworld

within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can signi„ cantly a‚ ect the function and/or structural integrity of the design. PRECAUTIONS: Interpret results with caution when using autorefractors or wavefront aberrometers that utilize infrared light, or when performing a duochrome test. Con„ rmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be a‚ ected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Synergy™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-in' ate the capsular bag at the end of the case. Residual viscoelastic and/or over-in' ation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Synergy™ Toric II IOL. All preoperative surgical parameters are important when choosing a TECNIS Synergy™ Toric II IOL for implantation, including preoperative keratometric cylinder (magnitude and axis), incision location, the surgeon's estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can in' uence patient outcomes and the e‚ ectiveness of treating eyes with lower amounts of preoperative corneal astigmatism. The e‚ ectiveness of TECNIS Synergy™ Toric II IOLs in reducing postoperative residual astigmatism in patients with preoperative corneal astigmatism < 1.0 diopter has not been demonstrated. Patients with a predicted postoperative astigmatism greater than 1.0 D may not be suitable candidates for implantation with the TECNIS Synergy™ and TECNIS Synergy™ Toric II IOLs, as they may not obtain the bene„ ts of reduced spectacle wear or improved intermediate and near vision seen in patients with lower predicted postoperative astigmatism. ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information. © Johnson & Johnson Surgical Vision, Inc. 2021 PP2021CT4750 Our most advanced TECNIS ® IOL yet, going beyond the limits of current trifocals. For more Breakthrough Innovations, visit our Johnson & Johnson Vision ASCRS Booth #2813 *vs. AcrySof ® IQ PanOptix, ® TECNIS Symfony,™ TECNIS ® Multifocal. Based on comparison of DFU defocus curves and head to head clinical study vs. PanOptix ® **Continuous 20/32 or better †vs. PanOptix ® IOL ‡Based on interim 6-months post-operative data Widest* range of continuous vision** with best near* 1-5 Superior image contrast † day and night, delivering vision that patients can trust 3 Excellent patient outcomes so they can enjoy the moments that matter most †‡6

• Blank Page
• Blank Page (1)